Earnings summaries and quarterly performance for OABI.
Executive leadership at OABI.
Board of directors at OABI.
Research analysts who have asked questions during OABI earnings calls.
Stephen Willey
Stifel Financial Corp.
4 questions for OABI
Matthew Hewitt
Craig-Hallum Capital Group LLC
3 questions for OABI
Puneet Souda
Leerink Partners
3 questions for OABI
Brendan Smith
Stifel, Nicolaus & Company, Incorporated
2 questions for OABI
Joseph Pantginis
H.C. Wainwright & Co.
2 questions for OABI
Srikripa Devarakonda
Truist Financial Corporation
2 questions for OABI
Conor Noel McNamara
RBC Capital Markets
1 question for OABI
Eric Carter
RBC Capital Markets
1 question for OABI
Jackson Schroeder
Craig-Hallum Capital Group LLC
1 question for OABI
Jacqueline Kisa
TD Cowen
1 question for OABI
Kripa Devarakonda
Truist Securities
1 question for OABI
Michael Sonntag
Leerink Partners
1 question for OABI
Recent press releases and 8-K filings for OABI.
- OABI reported Q3 2025 total revenue of $2.2 million, a decrease from $4.2 million in Q3 2024, with a net loss of ($16.5 million).
- The company updated its 2025 revenue guidance to a range of $18 to $22 million and operating expense guidance to $82 to $86 million, expecting to end the year with $52 to $56 million in cash.
- As of September 30, 2025, OABI continued to grow its business with 104 active partners and 399 active programs.
- A significant new technology, OmniUltra™, is scheduled for launch in December, which is anticipated to open important new markets and business opportunities.
- OmniAb reported Q3 2025 revenue of $2.2 million and a net loss of $16.5 million, or $0.14 per share.
- The company updated its 2025 financial guidance, now projecting revenue between $18 million and $22 million and operating expenses between $82 million and $86 million.
- OmniAb strengthened its balance sheet by completing a $30 million private placement, netting $28 million, and ended Q3 2025 with $59.5 million in cash.
- The company is launching OmniUltra in December, a new transgenic chicken platform designed to produce cow-like antibodies with ultra-long CDRH3s, which has the potential to open new markets in peptide therapeutics.
- OmniAb, Inc. (OABI) announced a definitive securities purchase agreement for a private placement of 21,254,106 shares of its common stock.
- The shares are being sold at a price of $1.40 per share, with officer and director participation at $1.85 per share.
- The private placement is expected to generate approximately $30 million in gross proceeds, which OmniAb intends to use for general corporate purposes and working capital.
- The transaction is anticipated to close on or about August 26, 2025.
Quarterly earnings call transcripts for OABI.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more